Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes.

This finding is consistent with results from the DIAN Study, in which an increase in CSF sTREM2 among autosomal dominant mutation carriers was found to differ from the level in normal controls 5 years before symptom onset, with this increase followed by Aβ, tau, and associated neurodegenerative changes; in advanced stages of the disease in the DIAN cohort, this difference did not reach statistical significance (Suárez-Calvet et al., 2016c ).

also in 111,027 other papers